This article is more than 5 years old. Information may no longer be current.
EPC-capture stent failed to reduce restenosis, TLR rates
Click Here to Manage Email Alerts
Endothelial progenitor cell-capture stents did not reduce the incidence of in-stent thrombosis and target lesion revascularization when compared with drug-eluting or bare-metal stents in a recent meta-analysis.
Researchers of the analysis enrolled 2,024 patients to investigate whether there was a difference in the clinical therapeutic effects between endothelial progenitor cell (EPC)-capture stents and DES or BMS.
According to results, there was no significant difference in the incidence of in-stent thrombosis between EPC-capture stents and DES/BMS. In a subgroup of 1,745 patients enrolled in the analysis of TLR, there was no significant difference in rate of TLR for patients treated with EPC-capture stents vs. DES/BMS.
However, compared with DES alone, TLR incidence for the EPC-capture stents significantly increased (RR=1.73; 95% CI, 1.01-2.94), as did the rates of cardiac death (RR=3.54; 95% CI, 1.13-11.08) and target lesion failure (RR=1.90; 95% CI, 1.05-3.45). There was no significant difference between BMS and EPC-capture stents in clinical events.
Researchers wrote that this observed incidence of TLR and cardiac death with EPC-capture stents must be confirmed in a randomized controlled trial to provide assurance with the results.
“In addition, there is a lack of pathological studies on patients with implanted EPC-capture stents, which makes it difficult to understand whether EPC-capture stents promote the repair of damaged endothelium and to determine the pathophysiological basis for the ineffectiveness of EPC-capture stents,” they wrote.
Disclosure: Liu reports no relevant financial disclosures.
Click Here to Manage Email Alerts